Patient characteristics
. | Standard myeloablative conditioning . | Reduced-intensity conditioning . | P . |
|---|---|---|---|
| No. (%) | 621 (74.3) | 215 (25.7) | |
| Period of transplantation, no. (%) | |||
| 1997-1998 | 268 (43.2) | 30 (14) | |
| 1999-2001 | 353 (56.8) | 185 (86) | |
| Male sex, no. (%) | 340 (54.8) | 121 (56.3) | |
| Median age, y (range) | 45 (18-67) | 56 (27-72) | <.001 |
| 35 y or younger, no. (%) | 135 (21.7) | 5 (2.3) | |
| 36-50 y, no. (%) | 315 (50.7) | 54 (25.1) | |
| Older than 50 y, no. (%) | 171 (27.5) | 156 (72.6) | |
| Male patient-female donor, no. (%) | 132 (21.3) | 50 (23.3) | |
| CMV risk group, no. (%) | <.005 | ||
| Patient+/donor+/- (high risk) | 275 (44.3) | 107 (50) | |
| Patient-/donor+/- (intermediate-low risk) | 70 (11.3) | 28 (13) | |
| Patient-/donor- (low risk) | 128 (20.6) | 21 (9.8) | |
| Last FAB disease classification, no. (%) | .007 | ||
| Secondary or therapy-related AML | 198 (37.4) | 75 (41.4) | |
| RA or RARS | 72 (13.6) | 20 (11.1) | |
| RAEB | 126 (23.8) | 59 (32.6) | |
| RAEB-t | 134 (25.3) | 27 (14.9) | |
| Unclassified MDS | 91 (14.7) | 34 (15.8) | |
| Response to chemotherapy at transplantation, no. (%) | .02 | ||
| Untreated | 234 (37.7) | 90 (41.9) | |
| First complete remission (CR-1) | 211 (34) | 66 (30.7) | |
| Non-CR-1 | 176 (28.3) | 59 (27.4) | |
| More than 10% blasts in BM at transplantation, no (%) | 73 (11.8) | 31 (14.4) | .04 |
| IPSS risk group, peak (% of cases with known IPSS)* | |||
| Intermediate-1 | 125 (34) | 38 (31) | .5 |
| Intermediate-2 | 99 (27) | 30 (25) | |
| High | 140 (39) | 54 (44) | |
| Cytogenetics, no. (%)† | |||
| Poor risk | 147 (59) | 41 (66) | .3‡ |
| Other (nonpoor risk) | 102 (41) | 21 (34) | |
| Not available | 372 | 153 | |
| Mo from diagnosis | .4 | ||
| Less than 3 | 289 (46.5) | 89 (41.4) | |
| 3 to 6 | 192 (30.9) | 69 (32.1) | |
| More than 6 | 140 (22.5) | 57 (26.5) | |
| Prior autologous HSCT, no. (%) | 68 (11) | 54 (25) | <.01 |
| Disease phase at transplantation, no. (%) | .3 | ||
| Early | 281 (45.2) | 85 (39.5) | |
| Nonearly | 227 (36.6) | 84 (39.1) | |
| Not available | 113 (18.2) | 46 (21.4) | |
| Stem cell source, no. (%) | <.001 | ||
| BM | 305 (49.1) | 27 (12.6) | |
| PBSCs | 316 (50.9) | 188 (87.4) | |
| CD34+ cells/kg cell dose infused, by stem cell source, no. (%) | |||
| PBSCs | 316 | 188 | |
| Below the median§ | 112 (23) | 60 (32) | .9 |
| Above the median§ | 113 (36) | 67 (36) | |
| Not available | 91 (29) | 61 (32) | |
| Bone marrow, no. (%) | 305 | 27 | |
| Below 2.2 × 106/kg§ | 69 (23) | 6 (22) | .8 |
| Above 2.2 × 106/kg§ | 91 (30) | 8 (30) | |
| Not available | 145 (47) | 13 (48) | |
| Median mo follow-up in survivors (N/%) | 50 (269/43) | 38 (93/43) | <.05 |
. | Standard myeloablative conditioning . | Reduced-intensity conditioning . | P . |
|---|---|---|---|
| No. (%) | 621 (74.3) | 215 (25.7) | |
| Period of transplantation, no. (%) | |||
| 1997-1998 | 268 (43.2) | 30 (14) | |
| 1999-2001 | 353 (56.8) | 185 (86) | |
| Male sex, no. (%) | 340 (54.8) | 121 (56.3) | |
| Median age, y (range) | 45 (18-67) | 56 (27-72) | <.001 |
| 35 y or younger, no. (%) | 135 (21.7) | 5 (2.3) | |
| 36-50 y, no. (%) | 315 (50.7) | 54 (25.1) | |
| Older than 50 y, no. (%) | 171 (27.5) | 156 (72.6) | |
| Male patient-female donor, no. (%) | 132 (21.3) | 50 (23.3) | |
| CMV risk group, no. (%) | <.005 | ||
| Patient+/donor+/- (high risk) | 275 (44.3) | 107 (50) | |
| Patient-/donor+/- (intermediate-low risk) | 70 (11.3) | 28 (13) | |
| Patient-/donor- (low risk) | 128 (20.6) | 21 (9.8) | |
| Last FAB disease classification, no. (%) | .007 | ||
| Secondary or therapy-related AML | 198 (37.4) | 75 (41.4) | |
| RA or RARS | 72 (13.6) | 20 (11.1) | |
| RAEB | 126 (23.8) | 59 (32.6) | |
| RAEB-t | 134 (25.3) | 27 (14.9) | |
| Unclassified MDS | 91 (14.7) | 34 (15.8) | |
| Response to chemotherapy at transplantation, no. (%) | .02 | ||
| Untreated | 234 (37.7) | 90 (41.9) | |
| First complete remission (CR-1) | 211 (34) | 66 (30.7) | |
| Non-CR-1 | 176 (28.3) | 59 (27.4) | |
| More than 10% blasts in BM at transplantation, no (%) | 73 (11.8) | 31 (14.4) | .04 |
| IPSS risk group, peak (% of cases with known IPSS)* | |||
| Intermediate-1 | 125 (34) | 38 (31) | .5 |
| Intermediate-2 | 99 (27) | 30 (25) | |
| High | 140 (39) | 54 (44) | |
| Cytogenetics, no. (%)† | |||
| Poor risk | 147 (59) | 41 (66) | .3‡ |
| Other (nonpoor risk) | 102 (41) | 21 (34) | |
| Not available | 372 | 153 | |
| Mo from diagnosis | .4 | ||
| Less than 3 | 289 (46.5) | 89 (41.4) | |
| 3 to 6 | 192 (30.9) | 69 (32.1) | |
| More than 6 | 140 (22.5) | 57 (26.5) | |
| Prior autologous HSCT, no. (%) | 68 (11) | 54 (25) | <.01 |
| Disease phase at transplantation, no. (%) | .3 | ||
| Early | 281 (45.2) | 85 (39.5) | |
| Nonearly | 227 (36.6) | 84 (39.1) | |
| Not available | 113 (18.2) | 46 (21.4) | |
| Stem cell source, no. (%) | <.001 | ||
| BM | 305 (49.1) | 27 (12.6) | |
| PBSCs | 316 (50.9) | 188 (87.4) | |
| CD34+ cells/kg cell dose infused, by stem cell source, no. (%) | |||
| PBSCs | 316 | 188 | |
| Below the median§ | 112 (23) | 60 (32) | .9 |
| Above the median§ | 113 (36) | 67 (36) | |
| Not available | 91 (29) | 61 (32) | |
| Bone marrow, no. (%) | 305 | 27 | |
| Below 2.2 × 106/kg§ | 69 (23) | 6 (22) | .8 |
| Above 2.2 × 106/kg§ | 91 (30) | 8 (30) | |
| Not available | 145 (47) | 13 (48) | |
| Median mo follow-up in survivors (N/%) | 50 (269/43) | 38 (93/43) | <.05 |
The IPSS risk group was not available in 257 (41%) and 92 (43%) patients in the standard myeloablative and reduced-intensity conditioning groups, respectively.
Available in detail in 311 patients.
Refers to the comparison of cytogenetic risk group in the 311 patients with available data.
CD34+ cell dose below and above the median (defined as 5.5 × 106/kg) for each stem cell source are classified as low and high cell dose infused, respectively.